Celldex Therapeutics (NASDAQ:CLDX) Earns Overweight Rating from Analysts at Morgan Stanley
Morgan Stanley began coverage on shares of Celldex Therapeutics (NASDAQ:CLDX – Free Report) in a report published on Thursday morning, MarketBeat reports. The brokerage issued an overweight rating and a $46.00 target price on the biopharmaceutical company’s stock. Other equities analysts also recently issued research reports about the company. The Goldman Sachs Group reduced their […]
Morgan Stanley began coverage on shares of Celldex Therapeutics (NASDAQ:CLDX – Free Report) in a report published on Thursday morning, MarketBeat reports. The brokerage issued an overweight rating and a $46.00 target price on the biopharmaceutical company’s stock. Other equities analysts also recently issued research reports about the company. The Goldman Sachs Group reduced their […]
